CIK 0001438533
- Large accelerated filer
Travere Therapeutics, Inc.
Sign in to watch- Ticker
- TVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- Operating
- EIN
- 262383102
- Phone
- +1 888-969-7879
- Business address
- 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Retrophin, Inc., Desert Gateway, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $79,495,607
- in 10 filings, $79.5M under 10b5-1 plans
Net −$79,495,607. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Dube Eric M −$38.5M CHIEF EXECUTIVE OFFICER sold 60% of stake
- Heerma Peter −$17.9M EVP, CHIEF COMMERCIAL OFFICER sold 71% of stake
- ROTE WILLIAM E. −$13.1M Chief Research Officer sold 68% of stake
- Cline Christopher R. −$3.2M CHIEF FINANCIAL OFFICER sold 37% of stake
- Inrig Jula −$2.8M EVP, Head of R&D & CMO sold 31% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-02-12 | ASELAGE STEVE Chief Executive Officer | Sale | −1,065 | $21.50 | $23K | 257,642 |
| 2019-02-11 | REED ELIZABETH E SVP, GC & Corporate Secretary | Sale | −885 | $21.38 | $19K | 15,442 |
| 2019-02-11 | ROTE WILLIAM E. Senior Vice President, R&D | Sale | −993 | $21.38 | $21K | 16,999 |
| 2019-02-11 | Clague Laura Chief Financial Officer | Sale | −1,017 | $21.38 | $22K | 11,016 |
| 2019-02-11 | ASELAGE STEVE Chief Executive Officer | Sale | −1,065 | $21.38 | $23K | 258,707 |
| 2019-01-09 | REED ELIZABETH E SVP, GC & Corporate Secretary | Sale | −750 | $23.82 | $18K | 16,327 |
| 2019-01-08 | REED ELIZABETH E SVP, GC & Corporate Secretary | Sale | −750 | $24.09 | $18K | 17,077 |
| 2019-01-04 | Dube Eric M Chief Executive Officer | Grant or award | +50,000 | 50,000 | ||
| 2019-01-04 | Dube Eric M Chief Executive Officer | Grant or award · Employee stock option (right to buy) | +400,000 | 400,000 | ||
| 2019-01-04 | Dube Eric M Chief Executive Officer | Grant or award · Performance-based restricted stock units | +50,000 | 50,000 | ||
| 2018-12-21 | ASELAGE STEVE Chief Executive Officer | Sale | −5,288 | $21.69 | $115K | 260,672 |
| 2018-12-21 | ASELAGE STEVE Chief Executive Officer | Sale | −900 | $22.35 | $20K | 259,772 |
| 2018-12-21 | Clague Laura Chief Financial Officer | Sale | −2,850 | $21.67 | $62K | 12,933 |
| 2018-12-21 | Clague Laura Chief Financial Officer | Sale | −900 | $22.34 | $20K | 12,033 |
| 2018-12-20 | McFarlane Neil F. Chief Operating Officer | Sale | −4,721 | $22.00 | $104K | 35,360 |
| 2018-12-20 | McFarlane Neil F. Chief Operating Officer | Sale | −6,404 | $22.56 | $144K | 28,956 |
| 2018-12-20 | ASELAGE STEVE Chief Executive Officer | Sale | −6,188 | $21.97 | $136K | 265,960 |
| 2018-12-20 | Clague Laura Chief Financial Officer | Sale | −3,750 | $22.08 | $83K | 15,783 |
| 2018-12-18 | Clague Laura Chief Financial Officer | Grant or award | +7,500 | 19,533 | ||
| 2018-12-18 | McFarlane Neil F. Chief Operating Officer | Grant or award | +11,125 | 40,081 |
Page 48 of 51 · 1,020 trades